Itamar Medical and SoClean will collaborate through its subsidiaries to make Itamar’s WatchPAT ONe test available to consumers.
Itamar Medical (NASDAQ:ITMR, TASE:ITMR) has announced that it and SoClean have entered into a collaboration through their subsidiaries to make Itamar Medical’s WatchPAT ONE home sleep apnea test and Digital Health Services available.
As quoted in the press release:
The collaboration is designed to overcome the barriers to sleep apnea testing and therapy solutions by enabling consumers to purchase remote sleep consultations and home-based sleep test using the WatchPAT ONE in the comfort of their own homes.
WatchPAT ONE is the first and only disposable home sleep apnea test (HSAT) cleared by the FDA. WatchPAT ONE provides an automated and comprehensive sleep report for interpretation and is simple to use with logistical advantages that are uniquely suited to the DTC market.
Under the terms of the collaboration agreement, SoClean’s Subsidiary (“SoClean”) will have exclusivity to market and sell the WatchPAT ONE to the DTC Segment in the United States, subject to purchasing certain minimum quantities. SoClean will have exclusive DTC rights in the U.S. through any and all marketing and sales channels, excluding healthcare providers and facilities and SoClean parent company has agreed to guarantee the performance of the collaboration by its subsidiary. SoClean plans to announce further details regarding its home sleep apnea testing service in Q1 2020.